10 results
CORRESP
BMY
Bristol-Myers Squibb Co.
18 Jan 22
Correspondence with SEC
12:00am
will be used in a singular manner or potentially in an alternative manner during its lifecycle. If the asset will be used only in a singular manner
425
BMY
Bristol-Myers Squibb Co.
30 Jan 19
Business combination disclosure
5:07pm
comes closer to the end of its lifecycle, and that’s a message that is really important for us, and it is resonating very well with the investment
425
CELG
Celgene Corporation
3 Jan 19
Business combination disclosure
5:21pm
IMMUNOLOGY & INFLAMMATION 9 CARDIOVASCULAR / FIBROSIS 10 PHASE III ASSETS 6NEAR-TERM POTENTIAL PRODUCT LAUNCHES SIGNIFICANT LIFECYCLE MANAGEMENT
425
gagzs0xw l4e
3 Jan 19
Business combination disclosure
5:18pm
8-K
EX-99.3
e8m5j0w315faoy
3 Jan 19
Regulation FD Disclosure
7:58am
425
EX-99.3
40f4h3wg2mozsg
3 Jan 19
Business combination disclosure
7:56am
- Prev
- 1
- Next